vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and Inhibikase Therapeutics, Inc. (IKT). Click either name above to swap in a different company.
Inhibikase Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $1.0M, roughly 1.0× AVAX ONE TECHNOLOGY LTD.). Inhibikase Therapeutics, Inc. runs the higher net margin — -1223.3% vs -1633.6%, a 410.2% gap on every dollar of revenue.
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
AVX vs IKT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.0M |
| Net Profit | $-16.6M | $-12.7M |
| Gross Margin | — | — |
| Operating Margin | -1522.1% | -1323.3% |
| Net Margin | -1633.6% | -1223.3% |
| Revenue YoY | — | — |
| Net Profit YoY | -480.2% | -5.0% |
| EPS (diluted) | $32.17 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.0M | ||
| Q3 25 | $525.9K | $0 | ||
| Q2 25 | $452.0K | $0 | ||
| Q1 25 | $344.4K | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $0 | $0 | ||
| Q2 24 | $41.3K | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-16.6M | $-12.7M | ||
| Q3 25 | $-8.4M | $-11.9M | ||
| Q2 25 | $-8.1M | $-9.9M | ||
| Q1 25 | $-145.5K | $-13.7M | ||
| Q4 24 | — | $-12.1M | ||
| Q3 24 | $-5.8M | $-5.8M | ||
| Q2 24 | $-4.2M | $-5.0M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 22.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 18.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1522.1% | -1323.3% | ||
| Q3 25 | -496.6% | — | ||
| Q2 25 | -328.4% | — | ||
| Q1 25 | -600.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2827.7% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1633.6% | -1223.3% | ||
| Q3 25 | -1588.0% | — | ||
| Q2 25 | -1783.4% | — | ||
| Q1 25 | -42.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -10243.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | $32.17 | $-0.10 | ||
| Q3 25 | $-5.55 | $-0.13 | ||
| Q2 25 | $-27.60 | $-0.11 | ||
| Q1 25 | $-1.17 | $-0.15 | ||
| Q4 24 | — | $0.88 | ||
| Q3 24 | $-57.19 | $-0.65 | ||
| Q2 24 | $-83.03 | $-0.66 | ||
| Q1 24 | — | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $218.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $187.0M | $172.9M |
| Total Assets | $195.0M | $181.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $218.3M | ||
| Q3 25 | $894.7K | $39.1M | ||
| Q2 25 | $185.3K | $9.9M | ||
| Q1 25 | $1.4M | $19.7M | ||
| Q4 24 | — | $138.6M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | — | $7.4M |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $187.0M | $172.9M | ||
| Q3 25 | $12.2M | $72.9M | ||
| Q2 25 | $4.1M | $80.1M | ||
| Q1 25 | $6.4M | $85.7M | ||
| Q4 24 | — | $94.9M | ||
| Q3 24 | $6.7M | $-530.6K | ||
| Q2 24 | $11.3M | $5.1M | ||
| Q1 24 | — | $6.8M |
| Q4 25 | $195.0M | $181.2M | ||
| Q3 25 | $16.5M | $79.6M | ||
| Q2 25 | $15.2M | $88.9M | ||
| Q1 25 | $16.8M | $94.3M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | $10.8M | $4.4M | ||
| Q2 24 | $15.7M | $8.8M | ||
| Q1 24 | — | $11.1M |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-7.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-7.5M | ||
| Q3 25 | $-2.4M | $-10.6M | ||
| Q2 25 | $-884.1K | $-5.6M | ||
| Q1 25 | $-2.2M | $-4.1M | ||
| Q4 24 | — | $-5.3M | ||
| Q3 24 | $-1.2M | $-4.9M | ||
| Q2 24 | $-919.2K | $-5.1M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
